Saturday 17 October 2026
Export AURA’s income statement to Excel — free account
Aura Biosciences, Inc.
AURA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 2.13% and free cash flow fell 56.3%, each against the same quarter a year earlier.
6.10
0.24
−3.79%
Follow AURA
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 5.42 | 6.94 | 20.90 | 18.81 | 18.76 | 10.77 | 8.15 |
Net Debt/EBITDA |
— | 1.37 | 0.81 | 4.33 | 3.19 | 2.70 | 1.59 | 1.29 |
Debt/Assets |
0.00% | 0.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.68 | 0.81 | 0.70 | 0.93 | 0.84 | 0.92 | 0.80 |
Capex/Depreciation |
— | 0.00 | (0.93) | (2.56) | (0.93) | (0.55) | (1.02) | (0.40) |
Interest Coverage |
— | (9,656.00) | — | — | — | — | — | — |
| — | 30.83% | 30.73% | (211.88%) | (33.78%) | (36.26%) | (46.01%) | (73.52%) | |
| — | (163.16%) | (101.87%) | (50.72%) | (30.61%) | (31.90%) | (39.73%) | (60.35%) | |
ROIC |
— | 0.00% | 0.00% | (682.29%) | (558.12%) | 0.00% | (6,857.59%) | 0.00% |
Return on Tangible Assets |
— | (98.04%) | (155.58%) | (30.47%) | (30.67%) | (34.33%) | (58.36%) | (79.26%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.71) | (68.37) | (6.69) | (1.86) | (1.63) | (1.63) | (1.41) |
Cash per Share |
— | 1.11 | 47.44 | 28.89 | 6.31 | 5.71 | 3.04 | 2.39 |
Shareholders Equity per Share |
— | 1.05 | (296.22) | 29.52 | 6.53 | 5.70 | 3.06 | 2.27 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 1.05 | (296.22) | 29.52 | 6.53 | 5.70 | 3.06 | 2.27 |
Free Cash Flow |
— | (20.67) | (25.09) | (34.53) | (55.69) | (64.56) | (81.06) | (85.19) |
Working Capital |
— | 27.20 | 15.79 | 146.35 | 186.25 | 219.44 | 145.71 | 131.36 |
Capital Expenditures |
— | (2.22) | (0.77) | (2.12) | (1.09) | (0.71) | (1.25) | (0.45) |
Net Current Asset Value |
— | 27.05 | (112.36) | 145.99 | 168.35 | 202.57 | 130.09 | 117.22 |
| Other line items | ||||||||
Quick Ratio |
— | 5.28 | 6.54 | 20.27 | 18.06 | 18.30 | 10.13 | 7.85 |
Depreciation/Fixed assets |
— | 0.14 | 0.23 | 0.16 | 0.22 | 0.41 | 0.38 | 0.43 |
Cash ROIC |
— | (32.66%) | 27.48% | (11.46%) | (14.49%) | (14.28%) | (26.75%) | (30.30%) |
Accounts Payable Turnover |
— | 0.35 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 1,672.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.71) | (66.27) | (6.28) | (1.82) | (1.61) | (1.61) | (1.40) |
Capex per Share |
— | 0.00 | (2.10) | (0.41) | (0.04) | (0.02) | (0.03) | (0.01) |
Average Payables |
— | 1.47 | 1.47 | 1.51 | 2.66 | 2.35 | 2.05 | 1.93 |
Average Assets |
— | 18.53 | 29.58 | 91.07 | 191.98 | 239.51 | 218.79 | 175.97 |
Average Common Equity |
— | (98.06) | (98.06) | 21.80 | 173.95 | 210.72 | 188.91 | 144.44 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates